NCT03006991

Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics

Individual Study of Methotrexate Based on Pharmacogenomics and Pharmacometrics

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Guangzhou Women and Children's Medical Center · Academic / Other
• Sex: All
• Age: 1 Month – 18 Years
• Healthy volunteers: Not accepted

Summary

This study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.

Detailed description

In order to find out "The critical reasons for individual variances in MTX of JIA pediatric patients and quantize the influence of these factors", based on early research, this study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.

Conditions

• Juvenile Idiopathic Arthritis

Interventions

Type	Name	Description
OTHER	therapeutic drug monitoring	dose of methotrexate can be adjusted by therapeutic drug monitoring.

Timeline

• Start date: 2016-11-01
• Primary completion: 2020-12-01
• Completion: 2023-12-01
• First posted: 2016-12-30
• Last updated: 2016-12-30

Locations

1 site across 1 country: China